证券代码：000813 证券简称：德展健康 公告编号：2023-061 德展大健康股份有限公司 关于参股公司合作研发项目临床试验进展的公告 北京东方略生物医药科技股份有限公司保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一 致。 德展大健康股份有限公司（以下简称"公司""德展健康"）于 2023 年 8 月 28 日收到公司参股公司北京东方略生物医药科技股份有限公司（以下简称"东 方略"）的告知函，东方略的美国合作方 Inovio Pharmaceuticals, Inc.（NASDAQ： INO）（以下简称"Inovio"）公司近日宣布决定在美国不再开展 VGX-3100 针对 宫颈癌前病变适应症的新的临床试验，但 Inovio 将继续推进 VGX-3100 在肛门/ 肛周癌前病变适应症的临床开发，同时，支持东方略积极推进 VGX-3100 在中国 的宫颈癌前病变适应症的三期临床试验，截至本公告日，国内试验入组人数已经 超过临床试验总人数的一半。有关情况具体如下： 二、美国试验对国内试验的相关影响 VGX-31 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥220,809,774.68, a decrease of 27.36% compared to ¥303,998,418.87 in the same period last year[21]. - The net profit attributable to shareholders of the listed company was a loss of ¥7,564,371.15, representing a decline of 111.55% from a profit of ¥65,512,052.62 in the previous year[21]. - The net cash flow from operating activities was ¥50,428,111.33, down 47.09% from ¥95,300,757.11 in the same period last year[21]. - The basic earnings per share were -¥0.0034, a decrease of 111.60% compared to ¥0.0293 in the previous year[21]. - The total revenue for the first half of 2023 was approximately ¥220.81 million, a decrease of 27.36% compared to ¥303.99 million in the same period last year[51]. - The company reported a significant decline in net profit after deducting non-recurring gains and losses, with a loss of ¥8,834,774.56 compared to a profit of ¥31,761,994.05 in the previous year, a decrease of 127.82%[21]. - The total comprehensive loss for the first half of 2023 was approximately ¥26.32 million, compared to a comprehensive income of approximately ¥40.67 million in the first half of 2022[164]. - The company reported a significant increase in management expenses, which rose to approximately ¥77.85 million in the first half of 2023, compared to ¥76.97 million in the same period of 2022[163]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,392,158,296.50, a decrease of 4.97% from ¥5,674,395,997.63 at the end of the previous year[21]. - The net assets attributable to shareholders of the listed company were ¥5,137,779,259.01, down 2.93% from ¥5,292,645,218.23 at the end of the previous year[21]. - Cash and cash equivalents at the end of the reporting period amounted to ¥2,883,416,008.22, representing 53.47% of total assets, an increase of 7.67% compared to the previous year[57]. - Accounts receivable decreased to ¥177,191,892.92, accounting for 3.29% of total assets, down by 2.60% year-on-year[57]. - Total liabilities decreased to CNY 281,769,223.11, a reduction of 27.8% from CNY 390,381,648.39[156]. Market and Business Strategy - The company is actively expanding into new business areas, including biopolypeptides, food and beverages, cosmetics, and influenza vaccines[29]. - The company aims to enhance brand recognition and customer loyalty through promotional activities and training programs for pharmacy staff[37]. - The company is focusing on risk resolution and governance to address various risk issues, including the ongoing resolution of disputes related to its subsidiary[45]. - The company is implementing marketing strategies to adapt to the challenges posed by volume-based procurement, aiming to stabilize and promote growth in the market[42]. - The company plans to invest approximately CNY 489.36 million in the Hainan Decheng International Health and Wellness Complex project, with a total construction area of about 71,828 square meters and a project duration of 33 months[133]. Research and Development - The company's R&D investment increased by 17.65% to ¥26.26 million from ¥22.32 million year-on-year[51]. - The company has a robust R&D platform with over 100 experienced professionals dedicated to product improvement and new drug development[48]. - The company plans to increase R&D investment to enhance the quality of its products and maintain a competitive edge in the market[77]. - The company has initiated research and development for new health products aimed at improving customer health outcomes[175]. Environmental Compliance - 嘉林药业的排污许可证有效期限为2021年12月3日至2026年12月2日[92]. - 嘉林药业在环保方面遵循了多项国家和地方的环境保护法规[90]. - The company has implemented strategies to enhance wastewater treatment processes[96]. - The company has established a wastewater treatment station that processes wastewater through multiple treatment stages, including screening and sedimentation[98]. - The company has a complete hazardous waste management system, including transfer slips and emergency response plans, compliant with local regulations[98]. Shareholder and Governance - The company has not encountered any issues or other situations in the use and disclosure of raised funds[70]. - The company’s board of directors approved the appointment of Mr. Xiao Jianfeng as the new deputy general manager, effective immediately[132]. - The company’s board of directors has undergone significant changes, including the resignation of the chairman and other key executives[132]. - The total number of common shareholders at the end of the reporting period is 47,021[141]. - The largest shareholder, Shanghai Yueye Equity Investment Management Partnership, holds 19.05% of the shares, totaling 414,138,066 shares[142]. Future Outlook - Future guidance suggests a cautious outlook, with expected revenue growth of 5% to 10% for the next quarter[175]. - The company expects to maintain a growth rate of over 20% in the next fiscal year based on current market conditions and strategic initiatives[184]. - The company plans to expand its market presence through new product launches and technological advancements in the upcoming quarters[179]. - The company is exploring potential mergers and acquisitions to enhance its competitive position in the health sector[179].

证券代码：000813 证券简称：德展健康 公告编号：2023-054 德展大健康股份有限公司 第八届董事会第十七次会议决议公告 本公司及其董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 德展大健康股份有限公司（以下简称"公司"）第八届董事会第十七次会议 的通知已于 2023 年 8 月 18 日以电子邮件方式发出；公司于 2023 年 8 月 21 日 10：00 分以通讯表决方式召开。应参加会议董事 9 人，实际参加会议董事 9 人， 会议由董事长魏哲明先生主持。本次董事会的召集、召开符合《公司法》及《公 司章程》的规定。 二、董事会会议审议情况 1、关于聘任公司副总经理的议案 为实现公司战略转型，加强公司经营管理团队建设，全面落实职业经理人管 理要求，进一步加快实施创新驱动战略，提升公司转型升级内生动力。经公司联 席董事长兼总经理刘伟先生提名，董事会提名委员会审核通过，聘任王曙宾先生 为公司副总经理，任期自本次董事会审议通过之日起至本届董事会届满止。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 为优化公司经营管理团队结构，提升经 ...

为实现公司战略转型，加强公司经营管理团队建设，提升经营管理效率，加 快实施创新驱动战略，加速公司技术创新和成果转化，提升公司转型升级内生动 力，全力推动公司高质量发展。德展大健康股份有限公司（以下简称"公司"） 于 2023 年 8 月 21 日召开了第八届董事会第十七次会议，审议通过了《关于聘任 公司常务副总经理的议案》《关于聘任公司副总经理的议案》《关于聘任公司首 席科学家的议案》，同意聘任张婧红女士为公司常务副总经理，协助总经理进行 企业全面管理工作，免去其副总经理职务，同时继续兼任公司财务总监；同意聘 任王曙宾先生为公司副总经理；同意聘任刘晔先生为公司首席科学家。上述人员 任期自本次董事会审议通过之日起至本届董事会届满止。 王曙宾先生长期从事药品研发及管理工作，具有丰富的药品研发及管理经验， 主导公司大麻二酚（CBD）治疗罕见病肺动脉高压新药、香叶基黄酮类化合物治 疗胰腺癌新药等 1 类创新药物研发工作，该研究目前已取得日本、澳大利亚、欧 洲、加拿大及美国 PCT 专利。 刘晔先生长期从事药品研发工作，曾任职于瑞典药物公司 Karo Bio AB 公司， 是公司全资子公司红惠新创始人，公司 WYY 项 ...

根据中国证监会《上市公司独立董事规则》《深圳证券交易所上市公司自律 监管指引第 1 号——主板上市公司规范运作》及《公司章程》等法律法规的有关 规定，我们作为德展大健康股份有限公司独立董事，就公司第八届董事会第十七 次会议聘任的常务副总经理、副总经理和首席科学家发表以下独立意见： 德展大健康股份有限公司 独立董事关于聘任公司常务副总经理、副总经理和首席科学家的 独立意见 （此页无正文，为公司独立董事关于聘任公司常务副总经理、副总经理和首席科 学家的独立意见签字页） 独立董事签字： 王新安 孙卫红 武 滨____________ 二〇二三年八月二十一日 经审阅张婧红女士、王曙宾先生、刘晔先生的个人履历等相关资料，我们认 为张婧红女士、王曙宾先生、刘晔先生具备相关专业知识和技能，任职资格符合 《公司法》和《公司章程》等有关规定。未发现有《公司法》规定的不得担任公 司高级管理人员等职务的情况，以及被中国证监会认定为市场禁入者或者禁入尚 未解除的情况。其选聘和提名程序符合《公司法》和《公司章程》的有关规定， 不存在损害公司及其股东利益的情况，其任职资格合法；我们同意聘任张婧红女 士为公司常务副总经理兼财务总监，王曙宾 ...

证券代码：000813 证券简称：德展健康 公告编号：2023-053 德展大健康股份有限公司 关于持股 5%以上股东股份被动减持股份暨 后续减持计划的预披露公告 美林控股集团有限公司保证向本公司提供的信息内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、美林控股在华福证券开展的质押式回购业务发生违约，华福证券通过集中 竞价方式对美林控股所持本公司 21,649,500 股股份进行强制卖出。 德展大健康股份有限公司（以下简称"德展健康"、"公司"或"本公司"） 于近日收到公司持股 5%以上股东美林控股集团有限公司（以下简称"美林控股"） 《关于美林控股被动减持股份暨后续减持计划告知函》，获悉美林控股所持本公 司 21,649,500 股股份发生被动减持，同时美林控股计划在未来三个月内以集中竞 价或大宗交易主动或被动减持本公司股份 21,734,809 股（含上述已减持 21,649,500 股股份，尚余 85,309 股股份未减持），即减持股份数量不超过公司总 股本的 1%。现将有关情况公告如下： 一、本次被动减持 ...

证券代码：000813 证券简称：德展健康 编号：2023-001 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活 □新闻发布会 □路演活动 动类别 □现场参观 □其他（请文字说明其他活动内容） 活动参与人员 保宁资本：黄静 时间 2023 年 6 月 28 日下午 地点 北京市朝阳区工体东路乙 2 号美林大厦 10 层公司会议室 形式 现场调研 上市公司接待 人员姓名 副总经理、董事会秘书：肖建峰；证券部：李萍 问题一、集采对于公司产品而言有何影响？ 答：近年来受集采政策影响，公司核心产品阿乐总体销量及销售收 入有所下滑，对公司总体营业收入构成一定影响。就公司目前业务 而言，阿乐仍然是公司的核心产品，未来尼乐作为新增重要品种， 将为公司巩固血脂调节剂市场形成补充。 交流内容及具 问题二、因为尼乐今年进入集采，所以销量会放大吗？ 体问答记录 答：尼乐今年 4 月份中标集采，确定了尼乐主供的区域包括河北、 山西、黑龙江、上海、安徽、四川、贵州等省份。尼乐（氨氯地平 阿托伐他汀钙片）2021 年 6 月收到国家药监局核准签发的《药品注 册证书》，成为首个获批的复方降压降脂国产药品。公司正在按 ...

证券代码：000813 证券简称：德展健康 公告编号：2023-036 德展大健康股份有限公司 关于参加新疆辖区上市公司 2023 年投资者 网上集体接待日活动的公告 本公司及其董事会全体成员保证信息披露内容的真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，德展大健康股份有限公司（以下简称"公 司"）将参加由新疆证监局、新疆上市公司协会与深圳市全景网络有限公司联合 举办的"2023 年新疆辖区上市公司投资者集体接待日活动"，现将相关事项公告 如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2023 年 6 月 16 日（周五）10:30-18:00，届时公司 高管将在线就公司 2022 年度业绩、公司治理、发展战略、经营状况、融资计划、 股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流，欢迎广 大投资者踊跃参与！ 特此公告！ 德展大健康股份有限公司董事会 二〇二三年六月十日 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB in 2022, representing a growth of 15% compared to the previous year[13]. - The company's operating revenue for 2022 was ¥570,855,435.18, a decrease of 22.28% compared to ¥734,479,885.95 in 2021[19]. - The net profit attributable to shareholders for 2022 was -¥46,908,665.33, an improvement of 18.54% from -¥57,581,886.98 in 2021[19]. - The total revenue for 2022 was CNY 570.86 million, a decrease of 22.28% compared to the previous year[54]. - The pharmaceutical sector generated CNY 562.19 million in revenue, representing 98.48% of total revenue and a decline of 20.05% year-on-year[56]. - The company reported a significant increase in cash flow from operations, indicating potential for improved liquidity and operational efficiency moving forward[19]. - The company achieved a net increase in cash and cash equivalents of ¥1,122,599,535.77 in 2022, a significant improvement from a decrease of ¥349,738,061.95 in 2021, reflecting a 420.98% change[71]. - The company reported a total investment of 91,611.08 million CNY for various projects, achieving 100% of the planned investment[86]. User Growth and Market Expansion - User data showed a rise in active users, reaching 5 million, which is an increase of 20% year-on-year[13]. - The company has set a future outlook with a revenue target of 1.5 billion RMB for 2023, indicating a projected growth of 25%[13]. - The company is expanding its market presence by entering two new provinces, aiming to increase market share by 10% in these regions[13]. - The company is expanding its market presence in Southeast Asia, targeting a 10% market share by the end of the next fiscal year[132]. - The company plans to enhance its digital platform, aiming for a 40% increase in online sales channels[132]. Research and Development - The company plans to invest 100 million RMB in R&D for new technologies over the next year[13]. - The company has established four specialized pharmaceutical research institutions with approximately 200 experienced R&D personnel, focusing on technological innovation and new drug development[43]. - The company has over 200 R&D personnel working on more than 20 projects, including several innovative drug candidates[50]. - The company is in the preclinical research phase for a new innovative drug targeting acute ischemic stroke, aiming for IND submission in approximately 1.5 years[67]. - The company has made progress in developing CBD-based treatments for rare diseases, with patent grants in major global markets[67]. - The company plans to accelerate the progress of R&D projects in 2023, with specific targets including entering clinical stages for the WYY project and ZT project, and achieving production approval for Trimetazidine Hydrochloride Tablets[100]. Strategic Acquisitions and Partnerships - A strategic acquisition of a local health tech firm was completed, valued at 300 million RMB, to enhance technological capabilities[13]. - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million RMB allocated for potential deals[127]. - The company has established partnerships with two major distributors to enhance its supply chain efficiency[127]. Operational Efficiency and Cost Management - The company aims to improve operational efficiency by reducing costs by 5% through process optimization initiatives[13]. - The company is actively pursuing cost reduction strategies, resulting in significant decreases in raw material costs[52]. - The company will implement cost reduction and efficiency enhancement strategies in 2023, aiming to improve capacity utilization and reduce unit costs through better supplier management and production technology innovation[101]. Risk Management - The management has identified potential risks including market competition and regulatory changes, with strategies in place to mitigate these risks[3]. - The company faces risks from market and policy changes, particularly due to the ongoing reforms in the pharmaceutical industry and stricter regulations[103]. - The company will manage production cost risks by establishing long-term partnerships with quality suppliers and innovating production processes[104]. Governance and Compliance - The company maintains complete operational independence from its controlling shareholder, Kaidi Investment, in terms of business, personnel, assets, and finance[112]. - The company has established a comprehensive financial management system, with independent accounting practices and tax obligations, ensuring no interference from the controlling shareholder[113]. - The company has a complete governance structure, with independent directors holding a majority in key committees, ensuring fair treatment of all shareholders[111]. - The company is committed to improving its governance structure by appointing qualified individuals to its board and management team[120]. Environmental Responsibility - The company has achieved compliance with national standards for pollution discharge in its production activities, with specific pollutant discharge limits outlined[172]. - The company has completed environmental impact report approvals for multiple projects, including the high Qing production base and Huan Tai medical beauty project[172]. - The company achieved a 100% compliance rate for wastewater discharge, meeting both Beijing and local sewage discharge standards[181]. - JiaLin Pharmaceutical invested approximately 2.01 million yuan in environmental governance and protection in 2022[180]. Shareholder Relations and Profit Distribution - No cash dividends will be distributed to shareholders for the fiscal year 2022, as the company focuses on reinvestment[4]. - The company reported a net profit attributable to shareholders of -46,908,665.33 CNY for 2022, with an initial undistributed profit of 3,894,471,040.61 CNY[151]. - The profit distribution plan for 2022 was deemed reasonable and compliant with relevant regulations, ensuring the protection of minority shareholders' interests[153]. Employee Management and Development - The total number of employees at the end of the reporting period was 1,082, with 30 in the parent company and 1,052 in major subsidiaries[147]. - The company has implemented various training programs, including professional skills training and safety management, targeting different employee groups[150]. - The company emphasizes the importance of adjusting the shareholding structure before project initiation to prevent external shareholders from influencing future investments[146].

Financial Performance - The company's revenue for Q1 2023 was ¥135,160,087.88, a decrease of 29.90% compared to ¥192,816,625.91 in the same period last year[5] - Net profit attributable to shareholders was ¥1,859,373.76, down 93.89% from ¥30,445,095.31 year-on-year[5] - The net cash flow from operating activities was ¥49,861,633.81, a decline of 61.77% compared to ¥130,435,562.96 in the previous year[5] - Basic and diluted earnings per share were both ¥0.0008, representing a decrease of 94.12% from ¥0.0136 in the same period last year[5] - Total operating revenue for Q1 2023 was ¥135,160,087.88, a decrease of 29.9% compared to ¥192,816,625.91 in the same period last year[22] - Net profit for Q1 2023 was ¥582,608.11, a significant decline from ¥22,929,114.75 in Q1 2022, representing a decrease of 97.5%[24] - Total comprehensive income for the period amounted to CNY 582,608.11, a decrease from CNY 22,929,114.75 in the previous period[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥5,554,524,795.94, down 2.11% from ¥5,674,395,997.63 at the end of the previous year[5] - Total assets decreased to ¥5,554,524,795.94 from ¥5,674,395,997.63, a reduction of 2.1%[21] - Total liabilities decreased to ¥328,445,794.71 from ¥390,381,648.39, a decline of 15.9%[21] Cash Flow - The company's cash and cash equivalents increased to ¥2,985,284,796.13 from ¥2,599,135,458.30 at the beginning of the year, reflecting a growth of 14.8%[20] - Cash inflow from investment activities reached CNY 400,005,200.00, significantly higher than CNY 80,551,396.03 in the previous period, indicating a growth of 396.5%[27] - Net cash flow from investment activities was CNY 386,383,653.20, compared to a negative CNY 15,445,078.29 in the previous period, showing a substantial turnaround[27] - Total cash inflow from operating activities was CNY 187,407,681.48, down from CNY 299,649,594.13 in the previous period, a decline of about 37.4%[26] - Total cash outflow from operating activities was CNY 137,546,047.67, compared to CNY 169,214,031.17 in the previous period, a decrease of approximately 18.7%[26] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 50,330[12] - Major shareholders include Meilin Holdings Group with 19.11% and Shanghai Yueye Equity Investment Management with 18.60%[13] - The company’s major shareholder, Meilin Holdings, holds 425,470,400 shares, representing 19.11% of the total share capital[17] - The company’s top ten shareholders include significant stakes from Xinjiang Kaidi Investment and Xinjiang Kaidi Mining, with holdings of 409,748,445 shares and 104,039,367 shares respectively[14] - The company’s top ten shareholders have a combined holding of 1.17% in the repurchase special account[15] Share Repurchase - As of March 31, 2023, the company repurchased a total of 26,105,140 shares, accounting for 1.17% of the total share capital, with a total payment of RMB 91,674,284 (excluding transaction fees)[15] - The company has repurchased a total of 25,323,440 shares, with the highest transaction price at RMB 3.88 per share and the lowest at RMB 2.94 per share, totaling RMB 88,756,868 (excluding transaction fees)[17] - The company’s total share repurchase reached 24,823,440 shares, approximately 1.11% of the total share capital, with a total payment of RMB 86,881,868 (excluding transaction fees)[16] - The company’s stock repurchase plan allows for a maximum reduction of 22,263,945 shares, not exceeding 1% of the total share capital[17] Investment and Projects - The company plans to invest approximately RMB 489.36 million in the Hainan Dezheng International Medical and Health Complex project, with a total construction area of about 71,828 square meters and a construction period of 33 months[17] - The company’s subsidiary, Jialin Pharmaceutical, participated in the eighth national centralized procurement and is expected to win the bid for Amlodipine Atorvastatin Calcium Tablets[17] Research and Development - Research and development expenses for Q1 2023 were ¥11,907,421.27, an increase of 11.1% compared to ¥10,715,438.38 in Q1 2022[22] Financial Expenses - The company reported a financial expense of -¥19,002,480.13, compared to -¥13,068,207.92 in the previous year, indicating an increase in financial costs[24] Audit Status - The first quarter report was not audited[28]